TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34480579
Drug: Daridorexant 150
Normalized name: Daridorexant
DrugBank: Daridorexant (DB15031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daridorexant 150 mg
Study: 34547081
Drug: Slower infusion
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slower infusion rate (333 mL/h)
Study: 34547081
Drug: Control infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control infusion rate (999 mL/h)
Study: 32715513
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) intervention, 8-week group-delivered
Study: 34041527
Drug: Headgear activator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Headgear activator treatment in mixed dentition (MD) starting at age 9
Study: 34041527
Drug: Headgear activator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Headgear activator treatment in late mixed dentition (LMD) starting at age 11
Study: 32811168
Drug: XEN 63
Normalized name: XEN-2174
DrugBank: XEN-2174 (DB05012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XEN 63 Gel Stent
Study: 34419109
Drug: Simethicone solution
Normalized name: Simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone solution intake 31‐60 minutes before procedure (group 2)
Study: 34419109
Drug: Simethicone solution
Normalized name: Simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone solution intake 20‐30 minutes before procedure (group 1)
Study: 34419109
Drug: Simethicone solution
Normalized name: Simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone solution intake > 60 minutes before procedure (group 3)
Study: 35594075
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab (IVB) with four monthly injections
Study: 35594075
Drug: Modified combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified combination group with two bimonthly IVB injections and modified laser therapy
Study: 34708929
Drug: Task-shared, nurse-delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-shared, nurse-delivered cognitive-behavioral therapy for adherence and depression (CBT-AD)
Study: 32196976
Drug: Tafamidis 61-mg
Normalized name: tafamidis 61 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafamidis 61-mg free acid capsules
Study: 32196976
Drug: Tafamidis meglumine
Normalized name: Tafamidis meglumine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tafamidis meglumine 80-mg (4 × 20-mg) capsules
Study: 32473644
Drug: Cardiac Shockwave
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac Shockwave Therapy (SWT) during CABG surgery
Study: 34143970
Drug: Avelumab plus
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab plus pegylated liposomal doxorubicin (PLD) (40 mg/m2 intravenously every 4 weeks)
Study: 32051303
Drug: Melatonin (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (four doses of 10 mg each)
Study: 32051303
Drug: Placebo (same
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (same dosing regime as melatonin)
Study: 34981479
Drug: Curcumin capsules
Normalized name: curcumin Oral Capsule
DrugBank: Curcumin sulfate (DB14635)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin capsules with piperine supplement (500 mg/day, 95% curcuminoids) for 8 weeks
Study: 35704960
Drug: Food supplement
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food supplement containing standardized menthol, limonene, and gingerol, administered for 30 days in addition to standard treatment.
Study: 35704960
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered for 30 days in addition to standard treatment.
Study: 34256715
Drug: Internet delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet delivered Cognitive Behavior Therapy with exposure (ICBT)
Study: 34256715
Drug: Internet delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet delivered Cognitive Behavior Therapy without exposure (ICBT-WE)
Study: 33257279
Drug: Dipyrone 25
Normalized name: dipyrone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 25 mg kg−1 every 24 hours
Study: 33257279
Drug: Dipyrone 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyrone 12.5 mg kg−1 every 12 hours
Study: 33257279
Drug: Meloxicam 0.1
Normalized name: MELOXICAM 0.15 g in 100 mL ORAL SUSPENSION [Metacam]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 0.1 mg kg−1 every 24 hours
Study: 33257279
Drug: Rescue analgesia
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue analgesia (tramadol, 2 mg kg−1 IV)
Study: 35803512
Drug: Operative analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative analgesic treatments with pharmacologic analgesia (OP) group, n = 30
Study: 33239135
Drug: Ginsenoside treatment
Normalized name: ginsenoside
DrugBank: Ginsenosides (DB14152)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginsenoside treatment
Study: 33991178
Drug: Sodium-glucose co-transporter-2
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium-glucose co-transporter-2 inhibitors (SGLT2i)
Study: 35377518
Drug: Onabotulinum toxin
Normalized name: tetanus toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onabotulinum toxin injections (12 units, 1:2.5)
Study: 35377518
Drug: Onabotulinum toxin
Normalized name: tetanus toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onabotulinum toxin injections (6 units, 1:5)
Study: 35377518
Drug: Onabotulinum toxin
Normalized name: tetanus toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onabotulinum toxin injections (4 units, 1:7.5)
Study: 35377518
Drug: 0.9% normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline injection
Study: 34215615
Drug: Control (non-HC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (non-HC treatment)
Study: 33202219
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg loading dose, 90 mg twice daily for 30 days)
Study: 33202219
Drug: Clopidogrel (300–600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (300–600 mg loading dose, 75 mg daily for 30 days)
Study: 36189651
Drug: Polynucleotides and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polynucleotides and hyaluronic acid based gel
Study: 32565458
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen + oral hydromorphone
Study: 32565458
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen + oral acetaminophen
Study: 35328964
Drug: Inertial training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inertial training (twice per week for 6 weeks, training load of about 70% of maximal force)
Study: 33974370
Drug: Isotonic ophthalmic
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic ophthalmic solution of 0.5% ozonised oil in liposomes plus hypromellose treatment (2 drops 4 times/day)
Study: 32419540
Drug: Fractional CO2-assisted
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO2-assisted photodynamic therapy (FrCO2 + PDT)
Study: 32925788
Drug: Acupoint thread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint thread embedding treatment
Study: 32925788
Drug: Climen tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Climen tablet (0.3 mg, 1 tablet/day)
Study: 36070301
Drug: oral alfacalcidol
Normalized name: alfacalcidol
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral alfacalcidol
Study: 34076288
Drug: Spironolactone therapy
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone therapy (Group PVI/SP)
Study: 36327532
Drug: Internet-based emotional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based emotional awareness and expression therapy (I‐EAET) for 10 weeks
Study: 34530594
Drug: Rivaroxaban (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (5 mg twice a day) alone
Study: 34530594
Drug: Aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (100 mg once a day) alone
Study: 36404687
Drug: Combined agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined agent flurbiprofen 8.75 mg and cetylpyridinium chloride 1.0 mg in the form of tablets for resorption
Study: 33491594
Drug: β-alanine supplementation
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-alanine supplementation (6.4 g·d-1) for 28 days
Study: 34281854
Drug: RANKL inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: RANKL inhibitors (RANKL-I)
Study: 33506810
Drug: Early low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early low-molecular-weight heparin (LMWH) administration within 7 days from COVID-19 signs and symptoms onset
Study: 33506810
Drug: Delayed low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed low-molecular-weight heparin (LMWH) administration after 7 days
Study: 33506810
Drug: Early low-molecular-weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early low-molecular-weight heparin (LMWH) administration
Study: 33811776
Drug: Adsorbent lotion
Normalized name: diphtheria toxoid adsorbed
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adsorbent lotion containing tapioca starch, spent grain wax, Butyrospermum parkii extract, argania spinosa kernel oil, aloe barbadensis, rosehip oil, and allantoin applied twice daily.
Study: 33811776
Drug: Adsorbent lotion
Normalized name: diphtheria toxoid adsorbed
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adsorbent lotion
Study: 33811776
Drug: 1% hydrocortisone
Normalized name: HYDROCORTISONE 0.01 g in 1 g TOPICAL OINTMENT [AFASSCO 1% Hydrocortisone]
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1% hydrocortisone cream applied twice daily.
Study: 33811776
Drug: Adsorbent lotion
Normalized name: diphtheria toxoid adsorbed
DrugBank: Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) (DB10584)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adsorbent lotion and 1% hydrocortisone cream
Study: 34238698
Drug: Ultrasound-guided BOTOX
Normalized name: Botox
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided BOTOX injection
Study: 34238698
Drug: Electrocauterization after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrocauterization after removal of apocrine sweat glands followed by ultrasound-guided BOTOX injection after two weeks
Study: 32481441
Drug: Sufentanil 1.78
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 1.78 µg/kg (group S)
Study: 32481441
Drug: Nalbuphine 1.78
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 1.78 mg/kg (group N)
Study: 32045638
Drug: HES50 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES50 (50 mg kg‐1 hesperidin)
Study: 32045638
Drug: HES75 (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES75 (75 mg kg‐1 hesperidin)
Study: 32045638
Drug: HES100 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES100 (100 mg kg‐1 hesperidin)
Study: 32045638
Drug: HES150 (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES150 (150 mg kg‐1 hesperidin)
Study: 32045638
Drug: HES50-150 (50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES50-150 (50-150 mg kg‐1 hesperidin)
Study: 34433653
Drug: Spartalizumab (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spartalizumab (400 mg once every 4 weeks)
Study: 34433653
Drug: Chemotherapy (per
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (per investigator's choice)
Study: 35077474
Drug: rasagiline (monotherapy)
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rasagiline (monotherapy)
Study: 34337284
Drug: ATTUNE knee
Normalized name: Bos taurus knee joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATTUNE knee implant system
Study: 34337284
Drug: P.F.C. SIGMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: P.F.C. SIGMA knee implant system
Study: 34987324
Drug: Dry needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry needling with conventional therapy
Study: 34987324
Drug: Neural mobilization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neural mobilization with conventional therapy
Study: 32966163
Drug: Self-reported success
Normalized name: black imported fire ant allergenic extract
DrugBank: Solenopsis richteri (DB11026)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported success in treatment, beliefs about the importance of multidimensional treatment, and self-reported empathy.
Study: 35932067
Drug: Transport PLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transport PLUS intervention (administered by trained EMTs)
Study: 35931131
Drug: Vaginal hysterectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal hysterectomy with uterosacral ligament suspension (USLS)
Study: 32777032
Drug: Highest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highest quartile of clinicians' antibiotic prescribing rate (80.2%)
Study: 32777032
Drug: Lowest quartile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lowest quartile of clinicians' antibiotic prescribing rate (42.1%)
Study: 35263558
Drug: Antihistamine-releasing contact
Normalized name: Ahist Antihistamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihistamine-releasing contact lens (etafilcon A with 0.019 mg ketotifen)
Study: 35263558
Drug: Placebo contact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contact lens (etafilcon A with no added drug)
Study: 32730798
Drug: Osilodrostat (1–30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osilodrostat (1–30 mg twice daily)
Study: 35789381
Drug: SER-109 (investigational
Approvals — FDA: no, EMA: no, PMDA: no
Description: SER-109 (investigational oral microbiome therapeutic)
Study: 34749808
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Calcium polyP microparticles (Ca‐polyP MPs) and biphasic calcium phosphate (BCP)
Study: 36275772
Drug: 50 µg
Normalized name: penicillin G 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 µg bivalent NoV vaccine
Study: 36275772
Drug: 150 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 µg bivalent NoV vaccine
Study: 36275772
Drug: Both dose
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dose levels of the vaccine
Study: 35875694
Drug: 1200 IU
Normalized name: Vitamin E 1200 IU Oral Capsule, Liquid Filled
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 IU (30 µg) capsules of vitamin D3 once per day
Study: 35875694
Drug: Placebo oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oil capsules once per day
Study: 32130806
Drug: Oral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral therapy with dolutegravir-abacavir-lamivudine
Study: 33081083
Drug: Rose extract
Normalized name: evening primrose extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rose extract treatment
Study: 33616606
Drug: Cancer drugs
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer drugs with positive reimbursement recommendation
Study: 33616606
Drug: Cancer drugs
Normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cancer drugs with negative reimbursement recommendation
Study: 34311777
Drug: Candidate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candidate treatment (specific candidates not mentioned)
Study: 32722956
Drug: 100 mg/day
Normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/day thiamin supplements
Study: 32968994
Drug: Second ARTA
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second ARTA therapy
Study: 34369452
Drug: Incremental vestibulo-ocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental vestibulo-ocular reflex (VOR) adaptation (IVA) training, once daily for 15 minutes over 6 months
Study: 34369452
Drug: x1 training,
Approvals — FDA: no, EMA: no, PMDA: no
Description: x1 training, once daily for 15 minutes over 6 months
Study: 32584828
Drug: Tracking of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tracking of daily prosocial behavior
Study: 35437302
Drug: Genetic screening
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic screening and insulin resistance markers
Study: 32938386
Drug: Dezocine 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dezocine 0.03 mg/kg (diluted to 5 mL)
Study: 34601233
Drug: Mindfulness-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based intervention (1-hour education session and daily mindfulness exercises during hospitalization)
Study: 34793637
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of ropivacaine 0.5% (experimental group)
Study: 34793637
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL of ropivacaine 0.5% (control group)
Study: 38939518
Drug: anti-PD1 treatment
Normalized name: Anti-PD1 / CTLA4 Bispecific Antibody XmAb20717
DrugBank: Vudalimab (DB18833)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-PD1 treatment
Study: 34171233
Drug: PCV10 vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV10 vaccination schedule (two-dose) at ages 2 and 6 months (group D)
Study: 32370765
Drug: Stereotactic ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic ablative radiotherapy (SABR) + standard of care (SOC) treatments
Study: 32370765
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) palliative-intent treatments
Study: 34875624
Drug: Evening whey
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening whey protein supplement
Study: 34098771
Drug: Control (simple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (simple hydration treatment)
Study: 34098771
Drug: Alprostadil treatment
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprostadil treatment
Study: 35988576
Drug: Upadacitinib 45
Normalized name: upadacitinib 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib 45 mg once-daily
Study: 35988576
Drug: Upadacitinib 15
Normalized name: upadacitinib 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib 15 mg once-daily
Study: 35988576
Drug: Upadacitinib 30
Normalized name: upadacitinib 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upadacitinib 30 mg once-daily
Study: 34293127
Drug: Low-sodium DASH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium DASH diet (1150 mg sodium)
Study: 34293127
Drug: High-sodium control
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sodium control diet (3450 mg sodium)
Study: 32161366
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (IN‐OT) administration (24 IU/day for 4 weeks)
Study: 33596412
Drug: WiSE system
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WiSE system (leadless endocardial system) for cardiac resynchronization therapy
Study: 32580161
Drug: Nordic hamstring
Normalized name: modified Vaccinia Ankara-Bavarian Nordic Injection [Jynneos]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nordic hamstring exercise training performed twice a week (n = 17)
Study: 32969758
Drug: Reldesemtiv (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reldesemtiv (all doses combined)
Study: 32474564
Drug: 24h-SIRI/B (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24h-SIRI/B (oral S-1 with 24-h infusion of irinotecan plus bevacizumab)
Study: 34613338
Drug: Genetically lower
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetically lower level of non-HDL cholesterol (17 mg/dL)
Study: 34946289
Drug: Intervention-1 (IG-1):
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention-1 (IG-1): Complementary training with traditional means of physical therapy
Study: 33407747
Drug: 25% albumin
Normalized name: Flexbumin 25% Albumin (Human) Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% albumin infusion
Study: 33407747
Drug: 0.9% sodium
Normalized name: LMD with 0.9% Sodium Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride infusion
Study: 35870895
Drug: Weekly physical
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly physical activity (PA) scheduled
Study: 35870895
Drug: Weekly energisers
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly energisers (short classroom PA breaks) scheduled
Study: 32826188
Drug: MMA injections
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMA injections combined with corticosteroids (ropivacaine, morphine, methylprednisolone)
Study: 36123067
Drug: CytoSorb haemoadsorption
Normalized name: DRESSING,CUTISORB ULTRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: CytoSorb haemoadsorption along with standard surgical treatment
Study: 36123067
Drug: Standard surgical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard surgical treatment alone
Study: 36167573
Drug: Oral co-trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral co-trimoxazole 960 mg once daily for 18 months
Study: 35861446
Drug: Subcutaneous hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous hydration (hypodermoclysis)
Study: 36305633
Drug: CJM112 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: CJM112 75 mg
Study: 32304353
Drug: Supportive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive group therapy (SGT)